biostudies-literatureAnderson ECU.S. Department of Health & Human Services | NIH | National Center for Advancing Translational SciencesNCATS NIH HHSU.S. Department of Health & Human Services | NIH | National Cancer InstituteHarold Alfond FoundationNCI NIH HHS67https://www.ebi.ac.uk/biostudies/studies/S-EPMC10924947biostudies-literatureUnknown8(1)Genomic tumor testing (GTT) is an emerging technology aimed at identifying variants in tumors that can be targeted with genomically matched drugs. Due to limited resources, rural patients receiving care in community oncology settings may be less likely to benefit from GTT. We analyzed GTT results and observational clinical outcomes data from patients enrolled in the Maine Cancer Genomics Initiative (MCGI), which provided access to GTTs; clinician educational resources; and genomic tumor boards in community practices in a predominantly rural state. 1603 adult cancer patients completed enrollment; 1258 had at least one potentially actionable variant identified. 206 (16.4%) patients received a total of 240 genome matched treatments, of those treatments, 64% were FDA-approved in the tumor typeNPJ precision oncologyGenome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).PMC10924947KL2TR002545P30 CA034196KL2 TR002545Han PKJDiPalazzo JBrooks PLGaitor LBourne JHelbig PSinclair SJRueter JGraham LRasmussen KHall MJAntov ABradford LSAnderson ECThomas CAInhorn RLucas FLLu-Emerson CLiu ETfalseGenome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI).Genomic tumor testing (GTT) is an emerging technology aimed at identifying variants in tumors that can be targeted with genomically matched drugs. Due to limited resources, rural patients receiving care in community oncology settings may be less likely to benefit from GTT. We analyzed GTT results and observational clinical outcomes data from patients enrolled in the Maine Cancer Genomics Initiative (MCGI), which provided access to GTTs; clinician educational resources; and genomic tumor boards in community practices in a predominantly rural state. 1603 adult cancer patients completed enrollment; 1258 had at least one potentially actionable variant identified. 206 (16.4%) patients received a total of 240 genome matched treatments, of those treatments, 64% were FDA-approved in the tumor type2024-01-01T00:00:00Z2024 Mar2025-04-04T12:58:39.898Z2025-04-04T12:58:39.898ZS-EPMC109249473846131810.1038/s41698-024-00547-4